By Billy Candra 
A groundbreaking study, recently published in the esteemed journal Nature Medicine, has illuminated a novel and highly promising therapeutic pathway in the relentless fight against cancer metastasis, a phenomenon responsible for the vast majority of cancer-related deaths worldwide. Researchers from a consortium of leading Swiss institutions, including ETH Zurich, the University Hospitals of Basel and Zurich, and the Basel-Land Cantonal Hospital, have demonstrated that the established heart medication digoxin can significantly weaken the clusters of circulating tumour cells (CTCs) responsible for spreading cancer, thereby substantially reducing the risk of metastasis formation. This finding offers a beacon of hope for patients grappling with aggressive tumour types, particularly metastatic breast cancer, and opens new avenues for therapeutic intervention.
The Lethal Challenge of Metastasis
Cancer metastasis remains the most formidable challenge in oncology, accounting for approximately 90% of all cancer fatalities, which tragically amount to around seven million lives globally each year. Unlike primary tumours, which originate and grow at a single site, metastatic tumours arise when cancer cells detach from the primary growth, infiltrate the bloodstream or lymphatic system, and journey to distant organs. These itinerant cancer cells, known as circulating tumour cells (CTCs), are the seeds of secondary tumours. A particularly insidious aspect of this process is the ability of CTCs to aggregate into small clusters, often comprising a handful to a dozen cells. These clusters possess enhanced survival capabilities in the hostile environment of the bloodstream and exhibit a significantly higher metastatic potential compared to single CTCs. Once these clusters successfully lodge in a new organ, they begin to proliferate, forming new, often treatment-resistant, metastatic tumours.
The formation of metastases dramatically alters the prognosis for cancer patients. For many cancers, including breast cancer, the five-year survival rate for localized disease can be exceptionally high, often exceeding 90%. However, once the cancer metastasizes to distant organs, this survival rate plummets precipitously, sometimes falling below 30%. This stark disparity underscores the critical need for therapies that can effectively prevent or disrupt the metastatic cascade. For breast cancer alone, a disease that affects millions globally and is the most common cancer among women, metastatic forms continue to claim the lives of tens of thousands of women annually, despite advancements in diagnosis and treatment. Oncologists have long sought strategies to disarm these circulating clusters, recognizing them as the Achilles’ heel of metastatic progression.
A Breakthrough in Clinical Application
The recent study represents a significant leap forward in this quest. In a carefully designed clinical study, researchers administered digoxin, a drug with a long history of use in cardiovascular medicine, at a low and safe dosage to nine patients with metastatic breast cancer for a period of one week. The results were compelling: a statistically significant reduction in the average number of cells per cluster was observed, decreasing by an average of 2.2 cells. While this number might seem modest in isolation, its impact is profound when considered in the context of typical cluster sizes, which are often composed of only a few cells. This reduction translates directly into a substantial weakening of the clusters’ ability to successfully establish new metastases.
Professor Nicola Aceto, the principal investigator and Professor of Molecular Oncology at ETH Zurich, emphasized the critical role of these clusters: "Breast cancer metastasis depends on CTC clusters. The larger they are, the more successful they are." His statement highlights the direct correlation between cluster size and metastatic efficiency. Smaller, more fragmented clusters are less resilient, less capable of surviving the journey through the circulatory system, and less adept at initiating tumour growth in distant organs. This targeted disruption of cluster integrity offers a promising new paradigm, moving beyond simply treating the primary tumour or established metastases to actively preventing their formation.
Unravelling the Scientific Mechanism
The effectiveness of digoxin against CTC clusters lies in its precise molecular mechanism, targeting a crucial component of cancer cell cohesion. The Achilles’ heel of these clusters, as identified by the research team, are the sodium-potassium pumps (Na+/K+-ATPases). These vital ion pumps are embedded within the membranes of tumour cells and play a fundamental role in maintaining cellular homeostasis by actively transporting sodium ions out of the cell and potassium ions into the cell. This delicate balance of ion concentrations is essential for numerous cellular processes, including cell adhesion.
Digoxin, a known inhibitor of Na+/K+-ATPases, effectively blocks the function of these ion pumps. By suppressing this critical ion exchange, digoxin disrupts the normal flow of ions across the cell membrane. This disruption leads to an increased influx and accumulation of calcium ions from the extracellular environment into the cytoplasm of the cancer cells. Elevated intracellular calcium levels, in turn, weaken the intricate molecular bonds and adhesion proteins responsible for holding the cancer cells together within the cluster. Consequently, the clusters begin to disaggregate, causing the cancer cells to fall apart and lose their collective metastatic advantage.
It is crucial to note that while digoxin effectively weakens and disbands CTC clusters, thereby mitigating the risk of metastasis, it does not, by itself, eliminate existing tumours. The drug’s primary action is prophylactic and anti-metastatic. For complete cancer eradication, digoxin would need to be administered in conjunction with other established therapies, such as chemotherapy, targeted therapies, or immunotherapy, which are designed to kill existing cancer cells. This positions digoxin as a potent adjuvant therapy, potentially enhancing the efficacy of current treatment protocols by addressing the often-overlooked and deadly process of metastatic spread.
From Foxglove to Clinical Breakthrough: A Chronological Journey
The journey to this significant discovery spans several years and highlights the power of systematic research and drug repurposing. Digoxin itself has a venerable history in medicine, tracing its origins back to the foxglove plant (Digitalis sp.). For centuries, extracts from this plant have been used for their cardiac effects, and digoxin specifically has been a mainstay in treating heart conditions such as heart failure due to its ability to strengthen heart muscle contractions.
The unexpected anti-cancer potential of digoxin in the context of CTC clusters first emerged in 2019 from the laboratories at ETH Zurich. Faced with the persistent challenge of metastasis, researchers embarked on an extensive and rigorous screening program. They systematically tested more than 2,400 different substances in cell cultures, meticulously evaluating their ability to act against clusters of circulating tumour cells. It was during this exhaustive screening process that digoxin stood out as a potent disrupter of CTC cluster integrity. This initial in vitro discovery laid the groundwork for the subsequent translational research, moving from laboratory bench to patient bedside, culminating in the recent clinical trial. The rapid progression from an initial screening hit to a proof-of-concept clinical study underscores the efficiency and strategic focus of the research team.
The Devastating Reality of Metastatic Breast Cancer
Breast cancer remains a global health crisis, with over two million new cases diagnosed annually, making it the most frequently diagnosed cancer among women worldwide. While early detection and advanced treatments have significantly improved outcomes for localized disease, the specter of metastasis continues to cast a long shadow. Once breast cancer cells spread beyond the breast and regional lymph nodes to distant sites like the bones, lungs, liver, or brain, it is classified as metastatic, or Stage IV, breast cancer. At this stage, the disease is generally considered incurable, and treatment focuses on prolonging life, managing symptoms, and preserving quality of life.
The stark reality is reflected in survival statistics: the five-year survival rate for localized breast cancer approaches 99%, dropping to around 86% for regional spread. However, for distant metastatic breast cancer, the five-year survival rate plummets to approximately 31%. This dramatic reduction in survival underscores the urgent need for innovative strategies to prevent metastasis. Current treatments for metastatic breast cancer, while increasingly sophisticated, often involve continuous systemic therapies, including chemotherapy, hormone therapy, targeted drugs (e.g., HER2-targeted therapies), and immunotherapies. While these treatments can extend life, they are often associated with significant side effects and ultimately face the challenge of drug resistance. The ability of digoxin to target the very mechanism of spread offers a new, complementary approach that could potentially alter the trajectory of this devastating disease.
Future Horizons: Optimisation and Broader Application
The success of this initial clinical study marks an important milestone, but it is by no means the end of the research journey. The researchers are already actively pursuing several exciting avenues for future development. One key focus is the optimization of the active ingredient itself. The ETH spin-off company, Page Therapeutics, has been established with the specific mission to develop new molecules based on the digoxin scaffold. The aim is to create compounds that are even more potent and selective in dissolving CTC clusters, potentially with an improved safety profile or pharmacokinetic properties that make them more suitable for long-term anti-metastatic therapy. This next generation of digoxin-derived drugs could represent an even more effective weapon against cancer spread.
Beyond breast cancer, Professor Aceto and his team are committed to expanding their research to other aggressive cancer types known for their propensity to metastasize. Initial experiments are already underway in the laboratory, investigating the efficacy of this approach in cancers such as prostate cancer, colorectal cancer, pancreatic cancer, and melanoma. These cancers collectively represent a significant global health burden, and if the principles of CTC cluster disruption prove effective across these diverse tumour types, the impact could be transformative. The underlying mechanism of cell adhesion and ion pump function is fundamental to many cell types, suggesting that the therapeutic potential of digoxin or its derivatives might extend broadly across the oncological landscape.
A Paradigm of Collaborative Excellence
The success of this study is a testament to the power of interdisciplinary collaboration, a hallmark of modern medical research. The project serves as a prime example of outstanding cooperation between a leading academic institution like ETH Zurich, renowned for its scientific innovation, and various clinical partners. The University Hospitals of Basel and Zurich, along with the Basel-Land Cantonal Hospital, played an indispensable role, not only in recruiting the patients essential for the clinical trials but also in meticulously conducting these trials with the highest standards of patient care and scientific rigor. This seamless integration of basic scientific discovery with clinical application is crucial for translating laboratory findings into tangible benefits for patients. Such synergistic partnerships are vital for navigating the complex journey from novel hypothesis to validated therapeutic strategy, ensuring that groundbreaking research can swiftly impact clinical practice.
Broader Implications for Cancer Treatment
The implications of this research extend far beyond the immediate findings for breast cancer. It heralds a potential shift in the overarching strategy for cancer treatment, moving towards a more proactive approach to metastasis prevention. By targeting the very mechanism of cancer spread – the circulating tumour cell clusters – this strategy offers a promising complement to existing therapies that primarily focus on eradicating the primary tumour or established metastases.
The development of therapies that specifically disrupt CTC clusters could significantly improve patient outcomes, reduce disease recurrence, and enhance overall survival rates. Furthermore, by potentially reducing the burden of metastatic disease, it could lead to a substantial improvement in the quality of life for cancer patients, sparing them from the debilitating effects of widespread cancer and intensive palliative treatments. From an economic perspective, reducing the incidence of metastatic disease could also alleviate a significant portion of the healthcare burden associated with the long-term management of advanced cancers. As research continues to unravel the complexities of cancer metastasis, the insights gained from studies like this one, focusing on novel targets and repurposed drugs, offer a renewed sense of optimism in the ongoing battle against this formidable disease.
